Abstract
This study used GC-MS analysis and computational biology to examine the diabetic effect of bioactive substances obtained from brown seaweed. Using AutoDock/Vina in Pymol 4.2, the molecular docking of Spatoglossum asperum on the human PPAR- protein was determined and compared to that of the well-known PPAR- agonist Gilbenclamide. The analysis the active components of seaweed extracts is the main focus of the current investigation. 12 substances were discovered using GC-MS analysis and evaluated using AutoDock/Vina against PPAR. Docking tests showed that the existing phytochemical 9-Octadecenoic Acid (Z)-, Octadecyl Ester, obtained from seaweed, has the highest fitness score of -398.9 kcal/mol and may therefore be a potent anti-diabetic drug. This study could result in the creation of brand-new marine nutraceuticals that use brown seaweed to treat a number of diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
